

Attorney Docket No.: 5440.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Re: U.S. Patent Application for
"Novel Mannanases"
Applicants: Kauppinen et al.

Sir:

Express Mail Label No. EL293689033US

Date of Deposit June 24, 1999

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Unexecuted Combined Declaration and Power of Attorney
4. Information Disclosure Statement
5. Copy of References
6. Certified Copy of Priority Applications

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Miriam Kelly

(Name of person mailing paper(s) or fee)

Miriam Kelly

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123

Attorney Docket No.: 5440.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Express Mail Label No.
Date of Deposit June 24, 1999

Sir:

This is a request for filing a **continuation** application under 37 C.F.R. 1.53(b)
of

Applicant(s): Kauppinen et al.

Title: Novel Mannanases

203 pages of specification 3 sheets of formal drawings 35 pages of Sequence Listing
3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee:	\$ 760.00
Total Claims: $31 - 20 = 11 \times 18 =$	\$ 198.00
Independent Claims: $6 - 3 = 3 \times 78 =$	\$ 234.00
Total Fee:	\$1,192.00

Priority of Danish application nos. PA 1998 01340, PA 1998 01341, PA 1998 01725, PA 1999 00306, PA 1999 00307, PA 1999 00308 and PA 1999 00309 filed on October 20, 1998, October 20, 1998, December 23, 1998, March 5, 1999, March 5, 1999, March 5, 1999 and March 5, 1999 is claimed under 35 U.S.C. 119. A certified copy thereof is submitted herewith.

Priority of U.S. provisional application nos. 60/106,054, 60/105,970, 60/123,543, 60/123,623, 60/123,641 and 60/123,642 filed on October 28, 1998, October 28, 1998, March 9, 1999, March 10, 1999, March 10, 1999 and March 11, 1999 is claimed under 35 U.S.C. 119.


The benefit of application no. 09/111,256 filed on June 10, 1999 in the U.S. and of application no. PCT/DK99/00314 filed June 10, 1998 via the PCT is claimed under 35 U.S.C. 120.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$1,192, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: June 24, 1999



Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123